Oncology drugs company Champions Oncology Inc (Nasdaq:CSBR) disclosed on Thursday loss from operations of USD619,000 for the first quarter ended 31 July 2017.
This marks an improvement of USD1.9m or (75.5%) when compared with the higher loss from operations of USD2.5m in the first quarter of fiscal 2017.
Revenue of USD5m were generated for the first quarter of fiscal 2018, up 37.1% over revenues of USD3.7m for the first quarter 2017.
Research and development (R&D) expense of USD1.1m was recorded for the three months ended 31 July 2017, a decline of USD100,000, or (7.7%) from R&D of USD1.2m for the three months ended 31 July 2016.
Bruker Corporation to acquire ELITechGroup for EUR870m, strengthening MDx portfolio
Perrigo announces quarterly dividend increase
Bruker expands Preclinical Imaging Portfolio with acquisition of Spectral Instruments Imaging
Fusion Antibodies announces receipt of follow-on project and provides R&D update
Alvotech reports positive results for AVT03, potential biosimilar to Prolia and Xgeva
Biosenic finalises agreement with Phebra for oral arsenic troxide development